Finance

Results: 13453-13464 of 49483

Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC

PR Newswire associated0

Philippe Brochard Joins Hanshow as Chairman of the Advisory Committee

PR Newswire associated0

When taking care of yourself is also a pleasure: Ibérico ham as a new icon of conscious eating

PR Newswire associated0

Under the Patronage of the Minister of Industry and Mineral Resources - Inauguration of the First Edition of the "Future Minerals Pioneers" Bootcamp

News Aktuell logo

ACOUSIA ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 PROHEAR STUDY EVALUATING ACOU085 (INN: BIMOKALNER) FOR THE PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY

PR Newswire associated0

Binance Launches First Regulated TradFi Perpetual Contracts Settled in Stablecoin, Starting with Gold and Silver

Experience Japanese Culture and Art at Keio Plaza Hotel Tokyo through Workshop Program Scheduled from January to April 2026

PR Newswire associated0

Sky Labs Secures CE-MDR for 'CART PLATFORM,' Accelerating Its Global Market Entry

PR Newswire associated0

Droit Launches Decision Decoder

Arne Boye Nielsen

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors

ACCESS Newswire logo

Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics